Enanta Pharmaceuticals | ENTA - Capital De Empréstimo





Capital De Empréstimo Alterar Data
AbbVie USD 58.94B 4.03B 2025-12
Amgen USD 51.89B 1.88B 2026-03
Arrowhead Research USD 538.1M 323.22M 2025-12
AstraZeneca USD 25.96B 177M 2026-03
BioCryst Pharmaceuticals USD 428.67M 234.31M 2025-12
Biogen USD 6.29B 1.7M 2026-03
Bristol-Myers Squibb USD 42.15B 698M 2026-03
Enanta Pharmaceuticals USD 0 0 2024-12
Gilead Sciences USD 22.13B 6M 2025-12
GlaxoSmithKline GBP 14.01B 696M 2026-03
Halozyme Therapeutics USD 2.14B 1.34B 2025-12
Heron Therapeutics USD 140.64M 975K 2025-12
Immunic USD 0 0 2024-06
Incyte USD 29.41M 785K 2026-03
Insmed USD 540.96M 1.24M 2025-12
Ionis Pharmaceuticals USD 1.91B 9M 2026-03
J&J USD 37.53B 1.91B 2026-03
Karyopharm Therapeutics USD 278.22M 278.22M 2025-12
Ligand Pharmaceuticals USD 445.49M 445.44M 2025-09
Merck USD 46.67B 77M 2026-03
Neurocrine Biosciences USD 169.5M 500K 2023-03
Novartis USD 37.45B 7.86B 2026-03
Novavax USD 246.3M 200K 2025-12
Pfizer USD 60.57B 1.08B 2026-03
PTC Therapeutics USD 2.03B 193.22M 2025-12
Roche Holding CHF 27.43B 966M 2025-12
Sarepta Therapeutics USD 828.97M 206.17M 2025-12
Vertex Pharmaceuticals USD 106.7M 4.7M 2025-12